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1. Introduction 
Mobilized peripheral blood stem cells (MPBSC) have nearly replaced bone marrow (BM). 
So, they become the primary source of hematopoietic grafts especially for patients with 
hematological malignancies undergoing aggressive myelosuppressive or myeloablative 
chemotherapy. It allows faster engraftment and equivalent disease-free survival compared 
with bone marrow cells [Siena S et al, 2000; To LB  et al, 1997; Roberto M. Lemoli and 
Alessandra D’Addio, 2008]. 
Some reports suggested that hematopoietic stem cell mobilization involves a complex 
interplay between adhesion molecules, cytokines, proteolytic enzymes such as MMP-9 and 
MMP-2, stromal cells and chemokines among them (e.g,; SDF-1/CXCR4) play a central role 
[Roberto M. Lemoli and Alessandra D’Addio, 2008; Tsevee Lapidot and Isabelle Petit, 2002]. 
It has been reported that increased secretion of SDF-1 downmodulates CXCR4 on CD34+ 
cells, thus preventing the homing of hematopoietic progenitors to the bone marrow 
[Signoret N et al, 1997]. Moreover, Dlubek D et al, have observed a negative correlation 
between mobilization capacity and a reduced expression of CXCR4 on mobilized HPC 
CD34+ in the leukapheresis product [Dlubek D et al, 2006]. 
These data suggested a central role for CXCR4 and SDF-1 on mobilization of hematopoietic 
stem cell as well as their homing to the bone marrow [Dlubek D et al, 2006]. 
The reason for poor mobilization of hematopoietic stem cells that occur in many donors or 
patients is fully recognized and patients’ characteristics (age, BMI, mobilization regimen, 
diagnosis and clinical status or ulterior therapy) did not explain the whole thing. 
Benboubker and his colleagues identified an association of a polymorphism in the SDF-1 
gene, designated as SDF1-3’A, with the rate of mobilization of HPCs CD34+ into peripheral 
blood [Benboubker L et al, 2001]. Hence, we hypothesized that individual genetic factors 
might explain, at least in part, this variability and that polymorphism analysis can be used 
to anticipate CD34+ cells mobilization.   
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So, identifying SNPs predictive of poor or good response to G-CSF or any mobilization 
regimen, in terms of number of CD34+ cells mobilized, might be useful in discussing the 
possibility of using a different mobilizing agent or a different source of CD34+ cells for auto-
HSCT and allo-HSCT.  
In this issue, we proposed to study the distribution of three genetic polymorphisms: SDF1-
3’A, MMP-9 C-1562T and GNB3 C825T in Tunisian patients with malignant hematological 
diseases who underwent stem cell mobilization for autologous transplantation compared to 
a group of healthy allogenic PBPC donors.   
2. Materials and methods 
2.1 Study population 
250 subjects (144 men, 106 women) admitted to the Cellular Immunology and Cytometry 
and Cellular Therapy Laboratory of National Blood Transfusion Center of Tunis –Tunisia, 
for autologous PBPC mobilization were enrolled.  
Our patients can be divided in 4 subgroups distributed as follows: Group 1: 85 Non-
Hodgkin’s Lymphoma (57 men, 28 women) which comprises 80 Diffuse B Cell Lymphoma, 
4 Mantle Cell Lymphoma and a patient with Follicular Lymphoma.  
Group 2: 87 Multiple Myeloma (48 men, 39 women).  
Group 3: 63 Hodgkin’s disease (31 men, 32 women).  
Group 4:  composed of 15 patients with Acute Myeloid Leukemia (9 men, 6 women).  
Besides, a group composed of 41 subjects (24 men, 17 women) with mean age of 32 years 
(range 12-63 years) designated for peripheral blood stem cells (PBSC) mobilization. They 
were visiting the Cellular Immunology and Cytometry and Cellular therapy Laboratory of 
National Blood Transfusion Center of Tunis–Tunisia as allogenic donors for stem cell 
transplantation.  
Then, a group of 165 healthy blood donors visiting the Blood Transfusion Service of 
National Blood Transfusion Center of Tunis -Tunisia served as a control group was enrolled 
in the study. Whole details concerning the subjects will be resumed in Table 1.  
Written informed consent was obtained from all subjects according to a protocol approved 
by the ethical committee for scientific and medical research of the National Blood 
Transfusion Center and National Bone marrow transplantation center of Tunis (Tunisia) in 
accordance with the Declaration of Helsinki.  
Circulating hematopoietic progenitors CD34+ were evaluated daily by flow cytometry and 
PBSC collections or apheresis were begun when peripheral CD34+ cells were ~20 cells/µl. 
Apheresis was usually performed daily using continuous flow blood cell separators COBE 
SPECTRA and MCS+. 
2.2 DNA extraction and genotyping 
Genomic DNA was prepared from EDTA anticoagulated peripheral blood by using a 
common salting-out procedure [Miller SA et al, 1988].  
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PATIENTS PBSC DONORS 
 
Total 
<2x10e6 
CD34+/kg 
>2x10e6 
CD34+/
kg 
p Total 
<3x106 
CD34/k
g 
≥3x106    
CD34/k
g 
 
Age (years) Median 40.58 
  
 
 
33.25 
(12-63) 
32.25 
(15-57) 
33.5 
(12-63) 
Range 12-64 
  
 
 
   
Male 144 27 117 NS 
 
24  6                   11 
Female 106 26 80  
 
17 6 6                   18 
Diagnosis 
   
 
 
   
NHL (non Hodgkin’s 
lymphoma)  
25 60  
 
   
Diffuse large Cell 
Lymphoma 
80 
  
 
 
   
FL(follicular 
lymphoma) 
1 
  
 
 
   
ML (mantle Cell 
lymphoma) 
4 
  
 
 
   
Hodgkin’s Disease 63 14 49  
 
   
Multiple Myeloma 87 12 77  
 
   
AML (acute myeloid 
leukemia) 
15 7 8  
 
   
Prior radiotherapy 62 19 23  
 
   
Prior chemotherapy 250 
  
 
 
   
time from last chemotherapy to 
mobilization    
 
 
   
< 1 month 121 - 
 
 
 
   
1 to 2 months 20 
  
 
 
   
2 to 3 months 4 
  
 
 
   
> 3 months 5 
  
 
 
   
Chemomobilization 
   
 
 
   
Rituximab ESHAP/         
rituximab DSHAP 
59 - 
 
 
 
   
rituximab CHOP 2 
  
 
 
   
ICE/ RICE 21 
  
 
 
   
Others 168 
  
 
 
   
Mobilization regimen 
   
 
 
   
growth factor only 
   
 
 
   
Lenograstim           
(Granocyte®) 
80 - 
 
 
 
   
filgrastim (Neupogen®) 75 - 
 
 
 
   
G/C [endoxan+ G-CSF] 95 - 
 
 
 
   
Table 1. patients and healthy allogenic PBPC donors charachteristics Abbreviations: G-CSF, 
granulocyte colony-stimulating factor; G/C, G-CSF- chemotherapy; ICE, ifosfamide, 
carboplatin, etoposide; ESHAP/DHAP, etoposide, cytarabine, methylprednisolone,  
www.intechopen.com
 Advances in Hematopoietic Stem Cell Research 
 
302 
2.3 Genotyping 
The reaction mixture consisted of 1µl PCR buffer 10x, 2 mM of MgSo4, 0.2 mM of each 
dNTP, 400mM of each primer, and 0,5units/reaction Taq DNA polymerase (Bio Basic Inc).  
The reaction conditions were: For SDF1–3’A an initial denaturation at 95°C for five minutes, 
then 35 cycles at 94°C for 30 seconds, at 58°C for 30 seconds, at 72°C for 1min, and finally 
extension at 72°C for 7 minutes.  
All specimens were examined for the presence of amplifiable DNA. PCR products were 
digested with 10units HpaII/reaction (Fermentas) at 37°C for overnight [Benboubker L et al, 
2001] (figure 1).  
For, MMP-9 C-1562T, PCR conditions as above, with annealing temperature at 67°C. PCR 
products were digested with 10units Hin1II/reaction (Fermentas) at 37°C for overnight 
[Zhang B et al, 1999; Toru Ogata et al, 2005] (figure 2). 
For GNB3 C825T, the PCR-reaction began with denaturation at 95°C for 5 min, followed by 
35 cycles of denaturation at 94°C (for 30 seconds), annealing at 55°C (30 s), extension at 72°C 
(1min), and a final extension at 72°C (7 min). PCR products were digested with BseDI at 
60°C (4 h), separated on 2% agarose gels, and visualized under UV illumination [Cheng-Ho 
Tsai MD et al, 2000] (figure 3) 
 
 
 
 
 
 
 
 
Fig. 1. SDF-1 genotyping by PCR-RFLP analysis followed by separation on 2% agarose gel as 
described in text. Lane 1, 100pb ladder; lanes 2 and 4, G/G; lanes 3 and 5, G/A; lane 11, A/A 
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Fig. 2. MMP-9 genotyping by PCR-RFLP analysis followed by separation on 2% agarose gel 
as described in text. Lanes 1 and 8, 100 pb ladder; lanes 2 and 6, C/C; lanes 3 and 9, C/T; 
lane 5, T/T. 
 
 
 
 
Fig. 3. GNB3 C825T genotyping by PCR-RFLP analysis followed by separation on 2% 
agarose gel as described in text. Lane 1, 100 pb ladder; lanes 2 and 3, C/T; lane 4, T/T;  
lane 5, C/C. 
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Table 2. All genotyping Details, corresponding to each polymorphism studied are provided. 
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2.4 Statistical analysis 
Allele and genotype frequencies of the studied polymorphisms in patients and healthy 
controls were formulated by direct counting. Statistical analysis was performed using SPSS 
software (SPSS 16.0 for windows; SPSS Inc., Chicago, IL.).  
The allele frequencies of SDF1-3’A, GNB3 C825T and MMP-9C-1562T polymorphisms were 
tested for the Hardy–Weinberg equilibrium of the whole group or subgroups of patients and 
were compared to the respective frequencies of the control group using the Pearson chi-square 
test or Fisher’s exact test when appropriate. The same test was applied to compare the 
genotype frequency between patients and controls. Association of the allelic frequencies with 
the clinico-pathologic parameters was evaluated by χ2 test. The odds ratios (OR) and 95% 
confidence intervals (CI) were calculated too. P<0.05 was required for statistical significance. 
3. Results 
3.1 Patient‘s distributions according to their CD34+ cell yield and failure rates 
Overall 83% of patients included in this study collected ≥2x106 CD34+ cells/kg after a 
maximum of 4 aphereses, among them 20% collected 2-5x106 CD34cells/kg, and 63% collected 
≥5x106 CD34 cells/kg. Beside, 10% are remobilizers as they did not achieve the threshold of 
CD34+ cell yield of 2x106 CD34/kg within 4 apheresis days and are subjects to another 
mobilization protocol.  Among them, the group of NHL represented the highest rate (40%), the 
lower ones, the group of MM and AML, which represented respectively 19% and 13%.  By 
contrast, others are designed as first mobilizers (90%) since they have already collected 
≥2x106CD34+ cells/kg after a maximum of 4 aphereses days.  Amongst them the group of 
multiple myeloma was the most frequent (40%), thereafter the group of Non-Hodgkin’s 
lymphoma (34%) and Hodgkin’s disease with 26%. For the patients included in this study, 
mobilization failure was defined as <2x106 CD34+ cells/kg obtained within 4 apheresis days. 
So, especially MM patients collected ≥5x106CD34+ cells/kg and contained the highest CD34+ 
cell yield (8,89x106 CD34/kg for MM, and 5,51x106 CD34/kg for the others patients). 
Furthermore, the fact that MM patients had higher yield of CD34+ cells compared to NHL and 
HD is likely since that NHL and HL patients are frequently more heavily pretreated with 
cytotoxic chemotherapy than patients with MM [Iskra Pusic et al, 2008] (figure 4). 
3.2 Analysis of the studied polymorphisms in the 4 subgroups of patients according 
to disease: A comparison between healthy donors of PBSC and patients 
According to this study, SDF1-3’A and MMP-9 C-1562 T polymorphisms were significantly 
different between the patients and healthy controls (table 3).  Particularly, we found 
significant differences in all the allelic and genotypic frequencies of the SDF1-3’A 
polymorphism in the MM group (p<0.05; OR=3.245 CI (95%)  [1.830-5.753] for A allele; p= 
0.017; OR= 3.324 CI (95%)  [1.182-9.348]; p= 0.009; OR= 2.072 CI (95%)  [1.200-3.580] for AA 
and GA genotypes, respectively).  
Concerning the MMP-9 C-1562 T polymorphism its distribution was significantly different 
in the same MM group of patients compared to the control group, significant differences 
were observed exclusively for the T allele (p=0.041; OR=2.295 CI (95%)  [1.020-5.168]) and 
also for the CC and CT genotypes (p= 0.039; p= 0.004; Table 3). 
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NHL
40%
AML
13%
MM
19% HD
28%
 
A number of first mobilization and remobilization in database 
Distribution of remobilizers in 
the 4 subgroup of patients 
 
 
 
Distribution of good and poor mobilizers of PBPC CD34+ in the study population and by sex 
 
 
Fig. 4. Overview of autologous stem cell transplantation database by disease as well as the 
distribution of good/poor mobilizers of PBSC CD34+ within the study population and by 
sex is already represented 
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Table 3. Allele and genotype frequencies of SDF-1, GNB3 and MMP-9 polymorphisms in the 
groups of patients with MM, NHL, Hodgkin’s’ Disease and AML 
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In table 3 are provided: all genotypic and allelic frequencies according to each polymorphism 
studied and corresponding to all patients. Distribution of genotypic and allelic frequencies by 
each disease included in this study. Then, all frequencies are calculated by statistical software 
SPSS 16.0 as well as p value and odd ratios (OR) are provided. 
For the group of NHL, the distribution of the SDF1-3’A polymorphism was significantly 
different between patients and healthy controls especially for the A allele which seemed to 
be associated to this disease (p=0,019).  Moreover, a decrease in GG genotype frequency 
compared to the control group was observed too reaching a statistically significance 
(p=0.029).  
Concerning the MMP-9 C-1562T polymorphism, like the MM group, high significant 
differences were seen especially for the T allele (P<0.05; OR=4.055; CI (95%) [1.901-8.646]) 
and CT genotypes (P<0.05; OR=6.333; CI (95%) [2.754-14.567]). Similar results were obtained 
concerning the distribution of the MMP-9 C-1562T polymorphism in the group of Hodgkin’s 
disease where significant differences were found in the T allele and CT genotype 
frequencies (p<0.05; Table 3). 
While, the distribution of the SDF1-3’A  polymorphism was not significantly different between 
the group of patients with AML and the control group, MMP-9 C-1562T distribution was 
significantly different essentially for the T allele (p=0.019, OR= 7.298, CI (95%)  [1.511-35.249]) 
and the CT genotypes (p=0.004, OR= 12.444, CI (95%)  [2.485-62.319]) Table 3.  
So the presence of the MMP-9 C-1562T might be associated with this disease. 
When considering the GNB3 C825T polymorphism, we observed that the TT genotype was 
more frequent in patient with MM and NHL with respectively 20.69% and 15.15% compared 
to the Hodgkin’s disease group (only 10.52%). Whereas, the CC genotype was more frequent 
in the NHL group (24.24%) (Table 3).  
3.3 Association of the SDF1-3’A allele with a good mobilizing capacity 
As the clinicians have defined mobilization failure as <2x106 CD34+ cells/kg obtained 
within 4 apheresis days, two mainly group of patients emerged: the subjects with a good 
capacity of mobilization who collected ≥2x106 CD34+ cells/kg obtained within 4 apheresis 
days. Others with a poor mobilizing capacity and didn’t collect 2x106 CD34+ cells/kg 
within 4 apheresis days. For the healthy allogenic PBSC donors, the mobilization failure was 
defined as <3x106 CD34+ cells/kg obtained within 4 apheresis days. 
When considering the SDF1-3’A polymorphism, significant difference was observed in the 
SDF1-3’A allele carriers and GG carriers (p=0.023). A higher concentration of CD34+ cells in 
the leukapheresis products was detected in SDF1-3’A positive patients compared to GG 
homozygous subjects 
Besides, a lower increase in the GG genotypes was observed in the “poor” mobilizer group 
compared to the “good” ones reaching a statistical significance (p=0.023; OR =0.494; CI 
(95%) [0.268-0.912]) (Table 4).  
Thus, the SDF1-3’A allele carriers, especially the SDF1-3’AA homozygous individuals in the 
group of healthy allogenic PBSC donors had a better mobilization potential (table 4). 
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Abbreviations: OR, odds ratio; af, allele frequency; gf, genotype frequency; CI, confidence interval 
(CI=95%); Corrected p value; NS, not significant; *, for SDF-1 polymorphism; ** for MMP-9 
polymorphism, Good mobilizers (>2X106 CD34/kg), Poor mobilizers (<2x106CD34/kg) 
 
Table 4. Allele and genotype frequencies of SDF-1, and MMP-9 polymorphisms in mobilized 
peripheral blood patients and healthy controls 
In this table are provided: 
All genotypic Allelic frequencies designed as “gf” and allelic frequencies designed as “af” of 
SDF1-3’A and MMP-9 C-1562T polymorphisms in all the study populations (all patients), 
then in a group of healthy blood donors (as control group) 
Then when, dividing the whole patients according to their mobilization capacity into: good 
mobilizers (>2X106 CD34/kg), and poor mobilizers (<2x106CD34/kg). 
OR designed as odd radio and p value of all genotypic and allelic frequencies are provided 
in the table by using statistical software (SPSS 16.0) as it was mentioned above in section 
materials and methods-statistical analysis. 
However, when considering the group of remobilizers in our study population we have 
observed that 48% of subjects were GG, 12% were AA and 40% were GA. This led us to 
consider a probable association of the GG genotypes to mobilization failure.  
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For the MMP-9 C-1562T polymorphism, significant difference was obtained with CT 
genotypes between the two groups (p=0.004; OR= 0.297; CI (95%)  [0.125-0.703]).  
For the GNB3 C825T polymorphism, we didn’t observe any difference between the 2 groups 
of poor and good mobilizers. 
This let us consider that there’s no association between GNB3 C825T polymorphism and the 
capacity of mobilization of hematopoietic stem cells. 
For the group of healthy PBSC donors, and with respect to our classification according to 
mobilization failure (<3x106 CD34/kg within 4 apheresis days), we have found an important 
association of SDF1-3’A distribution with higher mobilization yield of hematopoietic stem cells 
CD34+ reaching a higher statistical significance (p=0.001; OR=12.6; table 5).  
Besides, we have observed a similar increase in the SDF1-3’G allele in the intermediate to 
poor mobilizers’ subgroup reaching a statistical significance (p=0.035; OR=1.25; table 4). 
Similarly, the association was already observed when comparing the genotypic frequencies 
between the two subgroups.  
The AA genotype was absent in the poor mobilizer subgroup, then was highly increased in 
the other subgroup reaching a statistical significance (p=0.035; OR=1.25).  
While, the GG genotype was more represented in the poor mobilizers and the differences 
were significant too (p=0.001; OR=0.079; table 4). 
 
Healthy allogenic PBSC Donors 
Good mobilizers 
 
Poor mobilizers 
 
P OR CI 
       
 
N af 
 
N af 
  
 
32 0,55 
 
5 0,208 0,001§ 12,6 [2,407-65,953] 
26 0,45 
 
19 0,792 0,035§ 1,25 [1,045-1,495] 
N gf 
 
N gf 
  
 
3 0,10 
 
7 0,583 0,001§ 0,079 [0,015-0,415] 
20 0,69 
 
5 0,417 NS 
 
 
6 0,20 
 
0 0 0,035§ 1,25 [1,045-1,495] 
       
 
N' af 
 
N' af 
  
 
7 0,17 
 
6 0,23 0,633 (NS) 
 
 
33 0,82 
 
20 0,77 NS 
 
 
N' gf 
 
N' gf 
  
 
13 0,65 
 
7 0,54 NS 
 
 
7 0,35 
 
6 0,46 NS 
 
 
0 0 
 
0 0 NS 
 
 
Abbreviations: OR, odds ratio; af, allele frequency; gf, genotype frequency; CI, confidence interval 
(CI=95%); Corrected p value; NS, not significant; *, for SDF-1 polymorphism; ** for MMP-9 
polymorphism, for healthy allogenic PBPC donors: Good mobilizers (>3X106 CD34/kg), Poor 
mobilizers (<3x106CD34/kg) 
Table 5. Allele and genotype frequencies of SDF-1, and MMP-9 polymorphisms in  
mobilized peripheral blood of healthy allogenic PBSC donors 
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4. Discussion 
In the present study, we investigated the effect of polymorphisms in the genes SDF-1, GNB3 
and MMP-9 on the outcome of mobilization of peripheral blood stem cells for autologous 
transplantation by using a PCR-RFLP analysis.  
We observed a significant association for SDF-1 and MMP-9 polymorphisms exclusively in 
patients with MM, NHL and Hodgkin’s disease suggesting that these polymorphisms are 
fair candidate gene variants to these 3 hematological diseases.   
In fact, Association of these polymorphisms to cancer has been previously reported by many 
investigators [De Oliveira KB et al, 2009; Rabkin CS et al, 1999].  
Our results were in agreement with other studies suggesting that SDF1-3’A polymorphism 
is a genetic determinant of NHL [Gabriela Gonçavales de Olivera Cavassin et al, 2004]. 
Furthermore; as the SDF1-3’A polymorphism is situated in the mRNAs of 3’UTR region 
(untranslated region) which has been identified as an important regulator of the mRNA 
transcript, as well as the translated product [Catia Andreassi and Antonella Riccio, 2004; 
Marilyn Kozak, 2004; Gavin S. Wilkie  et al, 2003]. 
The second polymorphism studied encoded for MMP-9, J. Arai et al, have reported that SDF-1 
mRNAs abundantly expressed in stromal cells from the lymph nodes of patients with 
malignant lymphoma, so that 3’A carriers NHL are good candidates for presenting proliferation 
of neoplasic cells in the lymph nodes since that SDF-1 variant is associated with an increase of 
SDF-1 levels [J. Arai et al, 2000; Gabriela Gonçavales de Olivera Cavassin et al, 2004]. 
De Oliveira KB et al, when studying distribution of SDF1-3’A polymorphism have reported 
also a significant difference in genotype distribution between NHL patients (GG: 51.4%; GA: 
47.1%; AA: 1.5%) compared to healthy controls (GG: 65.6%; GA: 28.9%; AA: 5.5%). Whereas, 
they didn’t find any significant differences in genotypes distributions with breast cancer and 
Hodgkin’s lymphoma [De Oliveira KB et al, 2009].  
Moreover, previous reports on AIDS related non-Hodgkin’s lymphoma (NHL) 
demonstrated that the CXCL12–3’A chemokine variant was associated with approximate 
doubling of the NHL risk in heterozygotes and an approximately fourfold increase in 
homozygotes [Rabkin CS et al, 1999; A Zafiropoulos et al, 2004]. Hence, this might let us 
suggest the possible role of such variant in the pathogenesis of NHL. 
In this present work, we did not find a significant association between SDF1-3’A 
polymorphism and our group of patients with AML, this could be due to the lower number 
of patients (15 patients).  
However, Dommange et al, have reported the implication of SDF1-3’A polymorphism in the 
clinical representation of acute myeloid leukemia in 86 patients with AML, as an association 
between this polymorphism and the risk of tissue infiltration by malignant cell was 
established by an increased release of the blast from the bone marrow in the blood in the 
SDF1-3’A carriers suggesting that this SDF-1 variant is associated with clinical 
representation of AML [A Zafiropoulos et al, 2004].  
MMP-9 is a zinc-dependent proteinase, which is involved in numerous physiological and 
pathological processes. In the present study, we reported the distribution of the functional 
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MMP-9 polymorphism -1567 C/T in the promoter region of the MMP-9 gene in group of 
patients with some haematological malignancies as well as in patients undergoing stem cell 
mobilization.  
Then, we observed that the T allele was highly associated to the susceptibility to the four 
diseases studied (table 3). We have to investigate either this variant have major influence on 
the circulating levels of MMP-9. 
Concerning the group of MM, we observed a significant association in all allelic and 
genotypic frequencies of SDF1-3’A polymorphism with statistical differences when 
compared to control. Hence, as increased angiogenesis was related to the pathogenesis of 
MM, and because SDF-1 chemokine induces increased VEGF production, which is 
responsible for an angiogenic activity [Florence Dommange et al, 2006], we hypothesize that 
the SDF1-3’A polymorphism might increase SDF-1 protein which would have a role in 
developing angiogenesis and in the pathogenesis of the disease.                       
On the other hand, frequent distribution of the SDF-1 3’A allele in multiple myeloma 
patients confirms the implication of SDF-1 in hematopoietic stem cells. This logical 
consequence of the widely distribution of SDF-1 3’A allele proving that multiple myeloma 
patient’s could be considered as good mobilizers.  
For the GNB3 polymorphism we’ve observed that the TT genotype and the T allele 
frequencies are more frequent especially in patients with MM (0.72 for Tallele frequency) 
and NHL (0.45 for Tallele frequency) compared to healthy donors of PBSC ( peripheral 
blood stem cells) (Table 3) which is far from the others populations [Maggie C.Y et al, 2004] . 
Then, suggesting the possible relation with these diseases.  
Maggie et al when studying the ethnic differences in the linkage disequilibrium and 
distribution of single-nucleotide polymorphisms in 35 candidate genes for cardiovascular 
diseases have reported that the frequency of the T allele of GNB3 polymorphism in Chinese 
population is about 0.545. Then, such frequency is far from those of the French and of the 
Spanish population (0.329 and 0.359) and more closer to our result in Tunisian population 
[Yair Gazitt & Cagla Akai, 2004].  
When interesting to the capacity of mobilization which was largely demonstrated to vary 
from a subject to another, several studies have focused on such phenomena and have 
reported that 10–30% of patients with hematological malignancies fail to mobilize PBSC 
[Ingrid G. Winkler & Jean-Pierre Levesque, 2006] and either a small proportion of normal 
donors (1–5%) fail to mobilize sufficient CD34+ cells.   
Besides, many reports suggest that numerous factors are related to poorer mobilization 
including age, gender, type of growth factor, dose of the growth factor and in the 
autologous setting patient’s diagnosis, chemotherapy regimen and number of previous 
chemotherapy cycles or radiation [Sugrue MW et al, 2001].  
In our study we were interested in the possible implication of some genetic factors in 
mobilization and as we’ve found an association with the SDF-1 3’A variant only, then we 
supposed that this polymorphism is the only predictor of mobilization capacity of PBSC 
CD34+. 
www.intechopen.com
Distribution of SDF1-3’A, GNB3 C825T and MMP-9 C-1562T Polymorphisms  
in HSC CD34+ from Peripheral Blood of Patients with Hematological Malignancies 
 
313 
In fact, when analyzing the distribution of the two functional polymorphisms SDF-1 G801A 
and MMP-9 C-1562T considering the two groups of “good” and “poor” mobilizers, we’ve 
found an association only with SDF1-3’A polymorphism. While no association with capacity 
of mobilization was observed with GNB3 C825T and MMP-9 C-1562T polymorphisms.   
When observing the distribution of the two polymorphisms not only when considering the 
mobilization capacity but also in relation to each studied disease enrolled in this work we’ve 
found that the good mobilizer group was mainly composed of MM patients. Whereas the 
poor mobilizer group contains Hodgkin’s disease who are considered in previous studies as 
hard-to-mobilize patients [Benboubker L et al, 2001; Patrick J Stiff, 1999].  
The fact that multiple myeloma patients mobilized better PBSC CD34+ (peripheral blood 
stem cells) than the others groups seem to be related to their ulterior chemotherapy 
(dexamethasone + thalidomide) and didn’t receive any radiation therapy unlike the HD and 
NHL groups.  
In the good mobilizer group composed of patients needing fewer apheresis than the other 
group, genotypes frequencies for the GG,GA, AA represented  respectively 30.6%, 58% and 
11.4%, and corresponded respectively to 45.5%, 47% and 7.6%  in the poor mobilizer’s 
group,  and significant differences were found for GG genotype (p=0.007) and for A allele 
(p=0.009).  
This confirms on the one hand that the SDF1-3’A allele was associated with good mobilizing 
capacity not only in the group of patients but for instance in the group of healthy allogenic 
PBSC donors (see table 5). Thus, our results regarding patients undergoing autologous 
transplantation of haematopoietic stem cells concur with those reported by Benboubker et al 
[Bogunia-Kubik K et al, 2009].  
Moreover this deduction is already found in the group of healthy allogenic transplantation 
donors as it was reported in the present study and by Bogunia-Kubik K et al who have 
suggested that the SDF1-3’A allele was associated with a higher yield of CD34+ cells from 
healthy donors of PBPC for allogeneic haematopoietic SCT (stem cell transplantation) 
compared to GG homozygotes [Patrick J Stiff, 1999].  
Recent studies by the same group underlined an association of the SDF1-3’A allele with 
faster granulocyte and platelet recovery after transplantation. Therefore they suggested that 
the SDF-1 gene polymorphism could be a useful tool of prognostic value for recipients of 
autologous haematopoietic stem cells [A. Gieryng et al, 2010]. The allelic variant SDF1-3’A is 
a result of the SNP rs1801157, which is located in a highly demethylated area of the 3’UTR 
region. This SNP confers a G to A transition in the nucleotide position 801, resulting in a loss 
of a methylation site, which could affect the methylating effect of G-CSF [Nagler A et al, 
2004], and leading to a more decreased SDF-1 expression in healthy individuals carrying the 
polymorphism. 
So, it’s of interest to investigate either this variant have major influence on the circulating 
levels of SDF-1 and its mRNA expression, one of our future’s interests.  
Further studies examining how these three polymorphisms interact with disease risk factors 
are needed.  
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Interestingly, the possible implication of others genes involved of homing and migration 
process of CD34+ cells and for instance VCAM-1 to higher or lower mobilization yield of 
PBPC might emphasize new strategies for poor mobilizers subjects and lead to the 
identification of new biomarkers and/or therapeutic targets.  
5. Conclusion 
In the present study, we observed a significant association for CXCL12 and MMP-9 
polymorphisms exclusively in patients with MM, NHL and Hodgkin's disease suggesting 
that these polymorphisms are fair candidate gene variants to these 3 hematological diseases.  
Furthermore we've confirmed that the SDF1-3'A allele was highly associated to a good 
mobilizing capacity especially in the group of healthy allogenic PBSC donors where the 
analysis not biased by background disease or chemotherapy.  
Besides, we suggested a possible association of GG genotypes to poorer mobilization is 
already deduced. 
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